Lilly M&A streak rolls on with purchase of DNA delivery biotech
There’s no query Eli Lilly has been probably the most lively biopharma dealmaker of latest months, however even the billions the pharma already spent on acquisitions hasn’t exhausted its urge for food. The newest goal is California-based Engage Biologics, for which Lilly is paying $202 million. That quantity contains each an upfront payment and milestone…
